BioSpace News Archive

Amneal Pharmaceuticals, Inc. and Strides Pharma Science Limited announced the addition of Icosapent ethyl acid soft gel capsules, a product referencing VASCEPA®.

Ambio, Inc. announced today that a generic version of Forteo® 1 (teriparatide injection) developed by Ambio and to be marketed and sold by Apotex has been approved by the U.S. Food and Drug Administration (FDA).

Biovica International Biovica, active in cancer diagnostics, announces that the company has received a license for Maryland state, the 18th largest state in the US.

AC Immune SA, a clinical-stage biopharmaceutical company pioneering precision medicine for neurodegenerative diseases, announced the appointment, as of January 1st, 2024, of Dr. Madiha Derouazi as Chief Scientific Officer and the promotion of Interim Chief Financial Officer Christopher Roberts to Chief Financial Officer.

Foghorn® Therapeutics Inc. (Nasdaq: FHTX) today announced that clinical data from the Phase 1 dose escalation study of FHD-286 in acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) will be presented at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition, to be held December 9-12, 2023, in San Diego, California.

Nanoscope Therapeutics Inc., a late-stage clinical biotechnology company developing gene therapies for inherited retinal diseases and age-related macular degenerations (AMD), today announced that Francesco Bandello, MD, FEBO, will present at the 11th Annual FLORetina Congress taking place from November 30 - December 3, 2023 in Rome, Italy.

Castle Biosciences, Inc. announced the publication of a study in the Journal of the Advanced Practitioner in Oncology that assessed the viewpoints of NPs/PAs toward the clinical use of DecisionDx®-Melanoma in patients diagnosed with cutaneous melanoma.

HanchorBio Inc. today announced the acceptance of poster presentation at the European Society for Medical Oncology Immuno-Oncology (ESMO-IO) 2023 Annual Congress, taking place in Geneva, Switzerland and online from December 6-8, 2023.

Annovis Bio, Inc., a clinical-stage drug platform company developing novel therapies for neurodegenerative diseases such as Alzheimer’s and Parkinson’s disease announced the appointment of Andrew Walsh as VP, Finance.

Ovid Therapeutics Inc. today announced that five posters featuring data supporting its OV329 and OV350 programs for the potential treatment of epilepsies and treatment-resistant seizures will be presented at the 2023 American Epilepsy Society (AES) Annual Meeting in Orlando, Florida.